Assenagon Asset Management S.A. Sells 99,083 Shares of Haemonetics Corporation $HAE

Assenagon Asset Management S.A. cut its position in Haemonetics Corporation (NYSE:HAE) by 56.4% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 76,491 shares of the medical instruments supplier’s stock after selling 99,083 shares during the period. Assenagon Asset Management S.A. owned about 0.16% of Haemonetics worth $6,131,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the company. Central Pacific Bank Trust Division increased its holdings in shares of Haemonetics by 2.2% in the 4th quarter. Central Pacific Bank Trust Division now owns 8,900 shares of the medical instruments supplier’s stock worth $713,000 after buying an additional 188 shares during the last quarter. Quantinno Capital Management LP lifted its holdings in shares of Haemonetics by 9.0% during the 2nd quarter. Quantinno Capital Management LP now owns 3,492 shares of the medical instruments supplier’s stock worth $261,000 after acquiring an additional 289 shares during the last quarter. CWC Advisors LLC. lifted its holdings in shares of Haemonetics by 7.8% during the 3rd quarter. CWC Advisors LLC. now owns 4,551 shares of the medical instruments supplier’s stock worth $222,000 after acquiring an additional 328 shares during the last quarter. Creative Planning grew its position in Haemonetics by 3.3% in the second quarter. Creative Planning now owns 10,534 shares of the medical instruments supplier’s stock worth $786,000 after acquiring an additional 335 shares in the last quarter. Finally, True Wealth Design LLC grew its position in Haemonetics by 6,700.0% in the fourth quarter. True Wealth Design LLC now owns 340 shares of the medical instruments supplier’s stock worth $27,000 after acquiring an additional 335 shares in the last quarter. 99.67% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

HAE has been the topic of a number of research analyst reports. Citigroup reduced their target price on Haemonetics from $75.00 to $70.00 and set a “neutral” rating on the stock in a research note on Wednesday, March 11th. Needham & Company LLC cut Haemonetics from a “buy” rating to a “hold” rating in a report on Monday, December 15th. Barrington Research set a $94.00 price objective on Haemonetics in a research report on Friday, February 6th. Robert W. Baird set a $81.00 price objective on Haemonetics in a research report on Friday, February 6th. Finally, JPMorgan Chase & Co. boosted their target price on Haemonetics from $62.00 to $74.00 and gave the stock a “neutral” rating in a research report on Friday, December 12th. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and four have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $83.89.

Haemonetics Stock Down 2.8%

NYSE:HAE opened at $53.96 on Friday. The company has a debt-to-equity ratio of 1.01, a current ratio of 1.75 and a quick ratio of 1.15. The firm’s 50-day moving average price is $62.27 and its 200-day moving average price is $64.97. The company has a market capitalization of $2.51 billion, a PE ratio of 14.86, a P/E/G ratio of 1.13 and a beta of 0.28. Haemonetics Corporation has a 1-year low of $47.31 and a 1-year high of $87.32.

Haemonetics (NYSE:HAE) last announced its quarterly earnings data on Thursday, February 5th. The medical instruments supplier reported $1.31 earnings per share for the quarter, topping analysts’ consensus estimates of $1.27 by $0.04. Haemonetics had a net margin of 13.31% and a return on equity of 27.32%. The business had revenue of $338.97 million for the quarter, compared to analysts’ expectations of $331.90 million. During the same quarter in the prior year, the company earned $1.19 earnings per share. The business’s revenue was down 2.7% compared to the same quarter last year. Haemonetics has set its FY 2026 guidance at 4.900-5.000 EPS. On average, equities analysts predict that Haemonetics Corporation will post 4.55 EPS for the current fiscal year.

Haemonetics Profile

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.